Prevention of stroke with ticagrelor in Patients with Prior Myocardial infarction insights from PegasUs-tiMi 54 (Prevention of cardiovascular events in Patients With Prior heart attack Using ticagrelor compared to Placebo on a Background of aspirin-thrombolysis in Myocardial infarction
نویسندگان
چکیده
861 Marc P. Bonaca, MD, MPH Shinya Goto, MD Deepak L. Bhatt, MD, MPH P. Gabriel Steg, MD Robert F. Storey, MD Marc Cohen, MD Erica Goodrich, MS Laura Mauri, MD Ton Oude Ophuis, MD, PhD Mikhail Ruda, MD Jindřich Špinar, MD Ki-Bae Seung, MD Dayi Hu, MD Anthony J. Dalby, MD Eva Jensen, MD, PhD Peter Held, MD, PhD David A. Morrow, MD, MPH Eugene Braunwald, MD Marc S. Sabatine, MD, MPH Original research article
منابع مشابه
Balancing the risks and benefits of dual platelet inhibition.
Cardiovascular and cerebrovascular events commonly arise from atherosclerotic plaque rupture that produces platelet activation, thrombus formation, and reduction of blood flow to the brain or heart. The inhibition of platelets with aspirin is effective in the secondary prevention of acute coronary events.1 The addition of clopidogrel (i.e., dual antiplatelet therapy), a platelet P2Y12receptor a...
متن کاملImplications of the PEGASUS-TIMI 54 trial for US clinical practice
OBJECTIVES This study aims to determine the proportion of real-world patients with myocardial infarction (MI) who would have been eligible for the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) trial, to characterise their current use of P2Y12 inhib...
متن کاملLong-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.
BACKGROUND The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS We randomly assigned, in a double-blind 1:1:1 fashion, 21,162 patients who had had a myocardial...
متن کاملEfficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.
AIMS We evaluated the relationship of renal function and ischaemic and bleeding risk as well as the efficacy and safety of ticagrelor in stable patients with prior myocardial infarction (MI). METHODS AND RESULTS Patients with a history of MI 1-3 years prior from PEGASUS-TIMI 54 were stratified based on estimated glomerular filtration rate (eGFR), with <60 mL/min/1.73 m(2) pre-specified for an...
متن کاملIschaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
AIMS Ticagrelor reduced major adverse cardiovascular event (MACE) by 15-16% in patients with prior myocardial infarction (MI) in PEGASUS-TIMI 54. We hypothesized that patients who recently discontinued P2Y12 inhibition, even years after MI, may be at particular risk of MACE and may derive particular benefit from continuation or reinitiation of therapy. METHODS AND RESULTS Patients in PEGASUS-...
متن کامل